文献速递角膜与眼表疾病神经眼科

生长抑素通过调节巨噬细胞活动改善干眼病角膜神经异常与炎症

Somatostatin Ameliorates Corneal Nerve Abnormalities and Inflammation Through Regulation of Macrophage Activities in Dry Eye Disease.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

研究在泪腺切除诱导的干眼病小鼠模型中评估帕瑞肽(SOM230)对 corneal nerve abnormalities 的治疗作用及机制。SOM230 治疗显著改善角膜上皮完整性、减少疼痛行为并恢复角膜敏感性,RNA 测序显示其下调 TNF-α 和 NF-κB 等炎症通路,流式细胞术和免疫荧光显示其减少促炎 M1 巨噬细胞并增加抗炎 M2 巨噬细胞。结论认为 SOM230 通过抑制炎症通路和促进巨噬细胞从 M1 向 M2 极化转变来缓解干眼病神经异常,提示调节巨噬细胞极化是其治疗作用的关键机制。

要点

  • SOM230 改善干眼病小鼠角膜上皮完整性、减少疼痛行为并恢复角膜敏感性。
  • SOM230 下调 TNF-α 和 NF-κB 等关键炎症通路。
  • SOM230 减少促炎 M1 巨噬细胞并增加抗炎 M2 巨噬细胞。

核心结论

  • SOM230 通过抑制炎症通路(TNF-α、NF-κB)和促进巨噬细胞从促炎 M1 表型向修复性 M2 表型转变,缓解干眼病中的神经异常。
  • 调节巨噬细胞极化是 SOM230 治疗作用的关键机制,提示其作为干眼病神经损伤治疗策略的潜力。

研究设计与样本

  • 研究采用雄性 C57BL/6J 小鼠行泪腺切除术诱导干眼病模型,并给予 SOM230 或 PBS 治疗。
  • 评估指标包括角膜上皮完整性、疼痛相关行为和角膜敏感性。
  • 采用 RNA 测序鉴定 SOM230 调节的潜在通路,并用流式细胞术和免疫荧光定量巨噬细胞极化状态。

主要发现

  • 与 PBS 相比,SOM230 治疗显著改善角膜上皮完整性、减少疼痛行为并恢复角膜敏感性。
  • RNA 测序显示 SOM230 下调 TNF-α 和 NF-κB 等关键炎症通路。
  • 流式细胞术和免疫荧光显示 SOM230 减少促炎 M1 巨噬细胞并增加抗炎 M2 巨噬细胞,从而减轻角膜炎症并改善愈合。

临床怎么用

  • 原文结论指出 SOM230 具有作为干眼病神经损伤治疗策略的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to investigate the therapeutic effects of pasireotide (SOM230) on corneal nerve abnormalities in a mouse model of dry eye disease (DED) and to elucidate its potential mechanisms of action. METHODS: Male C57BL/6J mice underwent lacrimal gland excision (LGE) to induce DED and were treated with SOM230 or PBS. Corneal epithelial integrity, pain-related behaviors, and corneal sensitivity were evaluated. RNA sequencing was performed to identify potential pathways modulated by SOM230. Flow cytometry and immunofluorescence quantified macrophage polarization states. RESULTS: SOM230 treatment significantly improved corneal epithelial integrity, reduced pain behaviors, and restored corneal sensitivity compared to PBS. RNA sequencing revealed that SOM230 downregulated key inflammatory pathways, including TNF-α and NF-κB. Flow cytometry and immunofluorescence showed that SOM230 modulated macrophage polarization by decreasing pro-inflammatory M1 macrophages and enhancing anti-inflammatory M2 macrophages, contributing to reduced corneal inflammation and improved healing. CONCLUSIONS: SOM230 alleviates nerve abnormalities in DED by suppressing inflammatory pathways (TNF-α, NF-κB) and promoting a shift in macrophage polarization from the pro-inflammatory M1 phenotype to the reparative M2 phenotype. These findings suggest that modulation of macrophage polarization is a crucial mechanism underlying the therapeutic effects of SOM230, highlighting its potential as a treatment strategy for nerve damage in DED.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhu X, Ye H, Lu Y, et al. Somatostatin Ameliorates Corneal Nerve Abnormalities and Inflammation Through Regulation of Macrophage Activities in Dry Eye Disease. Invest Ophthalmol Vis Sci. 2025. PMID: 41201292. doi:10.1167/iovs.66.14.18

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。